Program
Pioglitazone
Also written as “pioglitazone”, “Pioglitazone 30 mg” and “Pioglitazone and azilsartan”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Alzheimer Disease · Fatty Liver · Peripheral Arterial Disease, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takeda | 330 open or running | phase 4since Jun 27, 2007 | Sep 9, 2005 | none ahead |
| Boryung Pharmaceutical | 42 open or running | phase 3since May 9, 2021 | May 9, 2021 | none ahead |
| Merck | 40 open or running | phase 3since Jul 22, 2008 | Aug 2, 2007 | none ahead |
| GlaxoSmithKline | 30 open or running | phase 4since Apr 2, 2009 | Dec 22, 2005 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 4since Oct 16, 2007 | Oct 16, 2007 | none ahead |
| Viatris | 20 open or running | phase 1since Mar 30, 2008 | Mar 30, 2008 | none ahead |
| dr-muhammad-abdulghani | 10 open or running | no phasesince Aug 16, 2016 | Aug 16, 2016 | none ahead |
| getz-pharma | 10 open or running | phase 4since Jul 19, 2021 | Jul 19, 2021 | none ahead |
| Medtronic | 10 open or running | early phase 1since Jul 21, 2008 | Jul 21, 2008 | none ahead |
| strekin-ag | 10 open or running | phase 3since Nov 1, 2017 | Nov 1, 2017 | none ahead |
Also a collaborator on its studies: parexel, zinfandel-pharmaceuticals-inc, Eli Lilly and takeda-pharmaceuticals-north-america-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 37 studies since Sep 9, 2005.
- Feb 1, 2011Phase 3 study in Diabetes Mellitus, Type 2Takeda · NCT01289119 · 506 enrolled · China, Hong Kong, Taiwan
- Sep 7, 2011Phase 1 study in Non-alcoholic Fatty Liver DiseaseMerck · NCT01431521 · 31 enrolled
- Oct 18, 2011Phase 1 study in HealthyTakeda · NCT01456117 · 61 enrolled · United States
- Aug 31, 2012Phase 4 study in Diabetes MellitusTakeda · NCT01686711 · 207 enrolled · Japan
- Aug 26, 2013Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseTakeda · NCT01931566 · 3,494 enrolled · United States, Australia, Germany and more
- Oct 24, 2013Phase 4 study in Diabetes Mellitus, Type 2Takeda · NCT01972724 · 114 enrolled · Korea, Republic of
- Nov 4, 2014Phase 3 study in Mild Cognitive Impairment Due to Alzheimer's DiseaseTakeda · NCT02284906 · 40 enrolled · United States, Australia, Switzerland and more
- Feb 19, 2015Phase 1 study in AnemiaGlaxoSmithKline · NCT02371603 · 70 enrolled · United States
- Aug 16, 2016dr-muhammad-abdulghani's first study: no phase study in Diabetes Mellitus, Type 2New to dr-muhammad-abdulghanidr-muhammad-abdulghani · NCT02887625 · 410 enrolled · Qatar
- Nov 1, 2017strekin-ag's first study: phase 3 study in Acute Hearing LossNew to strekin-agstrekin-ag · NCT03331627 · 165 enrolled · Czechia, Germany, Switzerland
- May 9, 2021Boryung Pharmaceutical's first study: phase 3 study in Type2 DiabetesNew to Boryung PharmaceuticalBoryung Pharmaceutical · NCT04885712 · 378 enrolled · Korea, Republic of
- Jul 19, 2021getz-pharma's first study: phase 4 study in Diabetes Mellitus, Type 2New to getz-pharmagetz-pharma · NCT04976283 · 123 enrolled · Pakistan
- May 26, 2022Phase 1 study in Diabetes Mellitus, Type 2Boryung Pharmaceutical · NCT05411965 · 48 enrolled · Korea, Republic of
- Jul 16, 20252 phase 1 studies in Diabetes MellitusBoryung Pharmaceutical · NCT07083401, NCT07083388
TargetBeta
“Peroxisome proliferator-activated receptor gamma agonist”ChEMBL 37, by rule
Other programs on PPARG
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| saroglitazarrule | Zydus Lifesciences | phase 4 | 19 |
| chiglitazarrule | Chipscreen Biosciences | phase 3 | 9 |
| lanifibranor | inventiva-pharma | phase 3 | 6 |
| T3D-959rule | t3d-therapeutics-inc | phase 3 | 3 |
Studies
All 52 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07083401Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 5, 2026 | 40 |
| NCT07083388Diabetes Mellitus · South Korea | 1 | Recruiting | Boryung Pharmaceutical | Jul 3, 2026 | 52 |
| NCT05411965Diabetes Mellitus, Type 2 · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Jul 3, 2022 | 48 |
| NCT04976283Diabetes Mellitus, Type 2 · Pakistan | 4 | UNKNOWN | getz-pharma | May 15, 2023 | 123 |
| NCT04885712Type2 Diabetes · Korea, Republic of | 3 | Completed | Boryung Pharmaceutical | Sep 19, 2022 | 378 |
| NCT03331627Acute Hearing Loss · Czechia, Germany, Switzerland | 3 | Completed | strekin-ag | Feb 6, 2020 | 165 |
| NCT02887625Diabetes Mellitus, Type 2 · Qatar | – | UNKNOWN | dr-muhammad-abdulghani | May 2017 | 410 |
| NCT02371603Anemia · United States | 1 | Completed | GlaxoSmithKline | Aug 12, 2015 | 70 |
| NCT02284906Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Switzerland and more | 3 | Terminated | Takeda | Jan 31, 2018 | 40 |
| NCT01972724Diabetes Mellitus, Type 2 · Korea, Republic of | 4 | Completed | Takeda | Oct 17, 2016 | 114 |
| NCT01931566Mild Cognitive Impairment Due to Alzheimer's Disease · United States, Australia, Germany and more | 3 | Terminated | Takeda | Jul 24, 2018 | 3,494 |
| NCT01686711Diabetes Mellitus · Japan | 4 | Completed | Takeda | Dec 2013 | 207 |
| NCT01456117Healthy · United States | 1 | Completed | Takeda | Jul 2012 | 61 |
| NCT01431521Non-alcoholic Fatty Liver Disease | 1 | Completed | Merck | Sep 18, 2012 | 31 |
| NCT01289119Diabetes Mellitus, Type 2 · China, Hong Kong, Taiwan | 3 | Completed | Takeda | Dec 2011 | 506 |
| NCT01124656Diabetes Mellitus, Type 2 | 3 | Terminated | Takeda | May 2007 | 26 |
| NCT01115712Overweight | 1 | Completed | Merck | Sep 2010 | 35 |
| NCT00879970Diabetes Mellitus, Type 2 · United States, Argentina, Canada and more | 4 | Terminated | GlaxoSmithKline | Nov 2010 | 1,332 |
| NCT00771004Coronary Artery Disease · Germany | 2 | Completed | Takeda | Feb 2009 | 63 |
| NCT00770952Diabetes Mellitus · Germany | 3 | Completed | Takeda | Dec 2008 | 91 |
| NCT00770653Diabetes Mellitus · Germany | 3 | Completed | Takeda | May 2009 | 305 |
| NCT00770640Diabetes Mellitus · Germany | 2 | Completed | Takeda | Jun 2010 | 40 |
| NCT00770575Cardiovascular Diseases | 2 | Completed | Takeda | Oct 2006 | 148 |
| NCT00770497Inflammation · Germany | 2 | Completed | Takeda | May 2008 | 172 |
| NCT00770445Diabetes Mellitus · Germany | 4 | Completed | Takeda | Jul 2010 | 121 |
| NCT00772174Diabetes Mellitus | 3 | Completed | Takeda | Feb 2008 | 418 |
| NCT00770835Diabetes Mellitus · Italy | 4 | Completed | Takeda | May 2011 | 39 |
| NCT00762736Diabetes Mellitus · United States, Argentina, Chile and more | 2 | Completed | Takeda | Oct 2005 | 704 |
| NCT00754403Diabetes Mellitus | 4 | Completed | Takeda | Oct 2006 | 312 |
| NCT00744367Diabetes Mellitus, Type 2 · United States, Brazil, Canada and more | 3 | Completed | Hoffmann-La Roche | Nov 2010 | 326 |
| NCT00727857Diabetes Mellitus · United States, Chile, Mexico and more | 3 | Completed | Takeda | Aug 2008 | 600 |
| NCT00722917Diabetes Mellitus · United States | 2 | Terminated | Takeda | Apr 2009 | 323 |
| NCT00722371Diabetes Mellitus, Type 2 | 3 | Completed | Merck | Oct 26, 2010 | 1,615 |
| NCT00720577Peripheral Arterial Disease | Early 1 | Completed | Medtronic | Jul 2007 | 164 |
| NCT00708175Glucose Metabolism Disorders · United States | 4 | Completed | Takeda | Jan 2011 | 156 |
| NCT00676260Diabetes Mellitus · United Kingdom | 2 | Completed | Takeda | Aug 2004 | 29 |
| NCT00672919Diabetes Mellitus · United States, Puerto Rico | 4 | Completed | Takeda | Aug 2004 | 305 |
| NCT00649558Healthy · United States | 1 | Completed | Viatris | Mar 2003 | 36 |
| NCT00649012Healthy · United States | 1 | Completed | Viatris | Mar 2003 | 40 |
| NCT00545233Hepatitis C, Chronic · United States, Puerto Rico | 4 | Completed | Hoffmann-La Roche | Dec 2010 | 155 |
| NCT00521820Diabetes Mellitus | 3 | Terminated | Takeda | Oct 2003 | 518 |
| NCT00521742Diabetes Mellitus | 3 | Completed | Takeda | Jan 2003 | 300 |
| NCT00511108Diabetes Mellitus, Type 2 | 1 | Completed | Merck | Feb 24, 2009 | 211 |
| NCT00494312Diabetes Mellitus | 4 | Completed | Takeda | Jun 2005 | 2,120 |
| NCT00395512Diabetes Mellitus · United States, Argentina, Australia and more | 3 | Completed | Takeda | Feb 2008 | 655 |
| NCT00376181Diabetes Mellitus, Type 2 · United States, Argentina, Chile and more | 3 | Terminated | Takeda | May 2007 | 96 |
| NCT00331487Diabetes Mellitus · United States | 3 | Completed | Takeda | Mar 2004 | 719 |
| NCT00328627Diabetes Mellitus, Type 2 · United States, Australia, Brazil and more | 3 | Completed | Takeda | Mar 2008 | 1,554 |
| NCT00269061Diabetes Mellitus, Type 2 · United States | 1 | Completed | GlaxoSmithKline | 32 | |
| NCT00225277Diabetes Mellitus · United States, Argentina, Canada and more | 3 | Completed | Takeda | Oct 2007 | 547 |
| NCT00225264Diabetes Mellitus · United States | 3 | Completed | Takeda | May 2006 | 458 |
| NCT00174993Diabetes Mellitus · Austria, Belgium, Czech Republic and more | 3 | Completed | Takeda | Jan 2005 | 4,373 |
How it is read
Names in the registry
- “Pioglitazone”, 33 entries
- “pioglitazone”, 5 entries
- “Pioglitazone 30 mg”, 4 entries
- “Pioglitazone and azilsartan”, 4 entries
- “TAK-379”, 3 entries
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 42 studies
- Diabetes Mellitus, 4 studies
- Alzheimer Disease, 2 studies
- Fatty Liver, 1 study
- Peripheral Arterial Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.